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ABSTRACT
Combinatory effects of the bioflavonoid apigenin with chemotherapeutic drugs on
prostate, colon, and lung cancer cell lines
Lesly Anne J. Lopez
Lung, prostate, and colon cancer are among the most commonly diagnosed cancers in
Americans. Current chemotherapeutic regimens generally have toxic side effects leading
to the death of normal cells. Polyphenols are naturally occurring compounds that can be
found in fruits, vegetables and herbs. Apigenin is a polyphenolic compound that has
been shown to have antioxidant and anti-inflammatory effects. In this study, apigenin
was shown to inhibit the proliferation of several cancer cell lines. The combination of 15
uM apigenin and the chemotherapeutic drugs including doxorubicin, etoposide,
mitomycin C, and 5-fluorouracil significantly decreased (P<0.05) the IC50 to inhibit the
proliferation of prostate cancer cell lines PC-3 and DU-145 more than the
chemotherapeutic drugs alone. Similarly, the addition of apigenin greatly enhanced the
sensitivity of colon cancer cell lines HCT-116 and colo-205 and lung cancer lines A549
and H460 to doxorubicin, mitomycin C, 5-fluorouracil, and cisplatin. We analyzed
sensitivity via cell death and cell proliferation assays.
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Chapter 1: Introduction
Although two-thirds of human cancers are preventable by lifestyle changes such as
dietary modifications (Katiyar et al 2001), the American Cancer Society reports that in
2005, 6.9 million patients will die of cancer and 10.9 million more will be diagnosed
world wide. In the US alone, 570,000 patients will die of cancer and nearly 1.4 million
new cases will be diagnosed. The leading cause of cancer death in America is lung cancer
followed by prostate cancer, with an expected 170,000 and 230,000 new cases to be
diagnosed. Colon cancer, the third most diagnosed cause of cancer in the US, will see
about 105,000 new cases in 2005.

Cancer, or the unregulated growth of cells in the body, can manifest itself in many
forms, but they all start out with damage to the DNA. Treatment varies widely with the
cancer’s point of origin and can vary within each type depending on the individual. Most
often, surgery is performed to physically remove the mass of cells. It is most successful
in cancers that have not yet spread to any other part of the body. The complications
involved with the surgical removal of cancer are the same with any surgical procedure
and can include bleeding, damage to internal organs and vasculature, an undesirable
reaction to anesthesia, and blood clots. Ionizing radiation is another common method
employed with cancer treatment. The power of radiation lies in its ability to physically
target rapidly dividing cells. Since growth patterns of cancer cells are abnormal and
unregulated, this makes the treatment particularly effective. Radiation can be employed
with either photons (x-rays or gamma rays) or particle radiation (alpha or beta particles,
protons, neutrons, electrons), but the complications are many. The treatment can only
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discriminate between radiosensitive and non-radiosensitive cells but not cancerous and
noncancerous cells, and commonly kills a number of normal cells in the body. The
patient undergoing radiation often experiences fatigue and loss of taste, and the patient’s
skin can undergo peeling and a pigment darkening.

Chemotherapeutic treatments of cancer involve the administration of any number of
anticancer drugs via oral, intravenous, or vaccine-like administration. The advantages to
chemotherapy over surgery and ionizing radiation are that does not rely on a trained eye
to be able to physically discern the cancer before being able to target it, and that it is
released into the bloodstream where it can then “seek out” the cancer throughout the
body. Like ionizing radiation, its power lies in its ability to target rapidly dividing cells.
However, because it works globally throughout the body due to its availability in the
blood stream, it also affects the body’s high-turnover cells like those in the stomach,
mouth, hair and nails. Common drugs include doxorubicin and etoposide for the
treatment of prostate cancer, 5-fluorouracil and platinum-based drugs for the treatment of
colon cancer, and paclitaxel and vinorelbine for treatment for lung cancer. Combinations
of chemotherapeutic drugs are common, such as the addition of leucovorin to 5fluorouracil, and can lead to less severe side effects.

Immunotherapeutic treatments of cancer involve stimulating the body’s own natural
defenses against invasion. The power of immunotherapy hinges on the often very
different characteristics of cancer cells and the body’s ability to recognize these cells as
abnormal. Treatment can take the form of cancer vaccination, administration of a
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monoclonal antibody therapy, or a nonspecific immunotherapy regimen that can boost the
body’s immune system overall. Because immunotherapy is a relatively new technique,
variety of treatment regimens are slim and little is known yet known about the long-term
effects.

Chapter 2: Review of Literature
Often, a patient’s treatment regimen includes a combination of techniques. Surgery
with followed by chemotherapy is a common regimen. Chemotherapeutic drugs affect
throughout the bloodstream, the drug’s mechanism must be eloquently designed in order
to affect only cancerous cells. This often means directing the drug towards the unique
characteristics of cancer cell and the way it can progress through the cell cycle. One
difference between cancer cells and normal cells is its p53-dependent status. When a
normal cell has damaged DNA, this signals the tumor-suppressor protein p53 and the cell
cycle kinase inhibitor p21 to activate (Manic et al 2003). This leads to an arrest of growth
in the G1 or G2 growth phase of the cell cycle, making it unable to for the damaged cell
to continue into mitosis (Cui et al 2002). If a particular form of cancer lacks these p53 or
p21 tumor suppressors, the cell cycle continues on having lacked any signal to turn itself
off. This leads to a proliferation of DNA-damaged cells.

A potential new cancer treatment also includes targeting the nuclear factor kappa B
(NF-kappaB) pathway. NF-kappaB has been implicated in regulation of cell growth,
apoptosis, inflammation and the stress response (Lin et al 2003, Li et al 2002, Karin et al
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2002). Its involvement on multiple cancers makes it a good target for chemotherapy. The
PI3K / AKT pathway activates a number of growth factors and cytokines unique to the
life span of a cancer cell. Its activation promotes cell survival by inhibiting apoptosis by
inactivating anti-apoptotic factors (Brenet et al 1999, Cardone et al 1998). The
overexpression of members of this pathway also make it a good target for
chemotherapeutic drugs. Another target of chemotherapy is the MAPK pathway, a threetiered kinase set consisting of MAP3K, MAP2K, and a MAPK, which can be ERK, JNK,
or p38. When activated, these MAPKs can lead to NF-kappaB, increased cell growth and
survival (Sebolt-Leopold 2000, Seger and Krebs 1995). These characteristics found in
cancer cells help make the MAPK pathway a useful target for chemotherapy.

Polyphenols are naturally-occurring antioxidants found in plants that have been
shown to have effects on biological activity. Classified as flavonoids, phenolic acids,
stilbenes, lignans, they are found in red wine, tea, fruits, and vegetables (Kuroda et al
1999). Recently, their antioxidant properties have been shown play a role in cell survival
(Chen et al 2000), cell cycle arrest (Yoshida et al 1990, Ranelletti et al 1992, Lepley et al
1996), and cell cycle enzyme arrest (Formica 1995, Cos et al 1998, Dugas et al 2000,
Pietta et al 2000). Naturally-occuring compounds like the flavonoids (Fig. 2.1), the most
abundant group of plant polyphenols, have been recently showed to inhibit tumor growth
(Formica and Regelson 1995, Kobyashi et al 2002). The chemopreventative effects of
these flavanoids have been studied in stomach, esophagus, duodenum, pancreas, liver,
breast, colon, lung, and skin cancers in addition to the elucidation of their role in
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atherosclerosis, cholesterol, and blood pressure (Nachshon-Kedmi et al 2002, Kim et al
1998, Kris-Etherton PM & Keen CL 2002).

Flavonoids have four subclasses divisible by structure, and each subclass has a
number of developing chemotherapeutic drugs (Table 2.1). The flavanols, flavones,
isoflavones, flavonols, and anthocyanidins have yielded enormous success as pre-clinical
trial chemotherapeutics (Gao et al 1999, Fotsis et al 1997). The structure of a flavonoid
itself is comprised of two benzene rings connected by an AC ring, with the C ring and
C2-C3 double bonds correlating with anti-proliferative activity and apoptosis (Deguchi et
al 2002, Choi et al 2005, Etherton et al 2002, Gao et al 1999, Gupta et al 2003).

One flavone of interest is apigenin, also known as 4’, 5, 7 trihydroxyflavone (Fig.
2.2). Apigenin has been classified as a nonmutagenic antioxidant and free radical
scavenger with low toxicity (Birt et al 1986, Duthie et al 2001). It has been to shown to
have anti-inflammatory properties in prostate cancer (Gupta et al 2001, Casagrande and
Darbon 2001), be able to arrest the cell cycle arrest in colon and prostate cancer (Wang et
al 2000, Gupta et al 2002) and to slow down growth and metastatic potential in
melanoma (Caltagrione et al 2000). In neuroblastoma, apigenin has the potential to
inhibit tumor growth, cell viability and induce caspase-dependent apoptosis in a p53
dependent manner in neuroblastoma and cervical cancer (Torkin et al 2005, Zheng et al
2005). Apigenin has also been shown to induce a dose-dependent phosphorylation of
ERK and p38 kinase but not JNK (Van Dross et al 2003), and to cause endothelial cell
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death with increasing reactive oxygen species levels via JNK- and p38 MAPK-responsive
activation (Choi et al 2005).

Previously, our laboratory has shown apigenin to inhibit VEGF / HIF-1 expression
through the PI3K / AKT and p53 pathways (Fang et al 2004). Previous work from our
laboratory showed that apigenin affects decreases cell proliferation in PC-3 and DU145
prostate cancer cells in a dose-dependant manner. Combining apigenin with cisplatin was
also shown to significantly decrease cell proliferation and increase apoptosis in a
cisplatin-resistant variant of the A2780 ovarian cancer cell line, CP70, over cisplatin
alone.

Currently, surgery or radiation combined with chemotherapy is the most common
treatment of cancer. However, standards of health can decrease due to the toxic effects of
any of these treatments. Radiation can decrease surfactant production so lungs don’t
inflate completely or cause stiffening or scarring, a condition called fibrosis. In the
prostate, sexual dysfunction can occur. A recent development in chemotherapeutics the
administration of drugs in combination to maximize cancer-killing properties with the
least amount of non-specific toxicity drugs are now being administered (Calviello et al
2005). Here, we propose that the non-mutagenic dietary flavanoid apigenin be combined
with current chemotherapeutic drugs to enhance their effects without additional toxic
effects.
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Chapter 3: Text of Investigation
In order to determine whether apigenin exerts a sensitizing effect on cancer drugs
undergoing chemotherapy, we chose a variety of cell lines: the p53 mutant prostate
cancer cell lines PC-3 and DU-145, the p53 mutant colo-205 and p53 wild-type HCT-116
colon cancer cell lines, and the p53 wild-type A549 and H460 lung cancer cell lines
(Table 3.1).

Materials and Methods
Cell Culture
PC-3 cells (ATCC CRL-1435) were grown in RPMI supplemented with 10% fetal calf
serum, 2 mM L-glutamine and 1 % penicillin/streptomycin. Subcultivation was
completed every 2-3 days with a 0.025% trypsin solution at a 1:10 ratio.
DU-145 cells (ATCC HTB-81) were grown in DMEM supplemented with 10% fetal
bovine serum, 2 mM L-glutamate and 1 % penicillin/streptomycin. Subcultivation was
done once every 6-7 days with at 0.025% trypsin solution at a 1:5 ratio.
Colo-205 cells (ATCC CCL-222) were grown in RPMI 1640 supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10
mM HEPES, 1.0 mM sodium pyruvate, and 1 % penicillin/streptomycin. Subcultivation
was done every 5-6 days with a 0.025% trypsin solution at a 1:5 ratio.
HCT-116 cells (ATCC CCL-247) were grown in McCoy’s 5a medium supplemented
with 10% fetal bovine serum, 1.5 mM L-glutamine, and 1 % penicillin/streptomycin.
Subcultivation was done every 3-4 days with a 0.025% trypsin solution at a 1:10 ratio.
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A549 cells (ATCC CCL-185) were grown in RPMI supplemented with 10% fetal calf
serum, 2 mM L-glutamate and 1 % penicillin/streptomycin. Subcultivation was done
every 2-3 days with a 0.025% trypsin solution at a 1:6 ratio.
H460 cells (ATCC HTB-177) were grown in RPMI supplemented with 10% fetal calf
serum, 2 mM L-glutamate and 1 % penicillin/streptomycin. Subcultivation was done
every 4-5 days with a 0.025% trypsin solution at a 1:8 ratio. All cells were incubated at
37 C in a 5% CO2 controlled environment and had their media refreshed every three days.

Drug Treatments
Chemotherapeutic drugs used include: doxorubicin hydrochloride, an inhibitor of
reverse transcriptase and RNA polymerase; cisplatin, a repair mechanism inhibitor;
etoposide, a DNA cleavage enhancer; mitomycin C, a DNA synthesis and nuclear
division inhibitor, and 5-fluorouracil, a DNA synthesis inhibitor. The chemotherapy
drugs doxorubicin, mitomycin C, etoposide, 5-fluorouracil, and cisplatin as well as the
flavanol apigenin were all obtained from Sigma Aldrich.

Cell proliferation assays
Cell proliferation assays were measured via MTT absorption. Cells were plated in
96-well plates (Corning Life Sciences) at 1x104 cells per well in 100 uL of feeding media
and were allowed to adhere overnight. The next day, the media was removed and
replaced with fresh medium or treatment doses. Cells were incubated at 37 C for 24 hours
before the addition of 10 uL of 5 mg/mL thiozolyl blue tetrazolium bromide reagent
(Sigma Aldrich). After another 2 hr incubation, the reaction was stopped by adding 100
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uL of solubilization solution. Measurements were taken using a spectrophotometer at 470
nm after 4 hours.

Cell Death:
Cell death was measured via trypan blue exclusion. Cells were plated at 1x106 in
6 well plates and allowed to adhere overnight. The next day, the plating medium was
removed and cells were washed with 1x PBS before serum starving for 8 hours. The
media was then refreshed and drug treatments administered for 6 hours. The cells were
then washed with 1x PBS, detached with 0.025% trypsin, spun at 2000 RPM at 4 C for 5
minutes, aspirated, and resuspended in 1 mL 1x PBS. An aliquot of this suspension was
then stained with an equal volume of trypan blue (Gibco-BRL) and counts of live and
dead cells were done using a hematocytometer.

Statistical Analysis
Significant differences were calculated using ANOVA with p<0.05. IC50’s were
calculated using a regression calculation.

Chapter 4: Summary and Conclusions
Summary
Effects of Apigenin on Different Cell Types
To study the effect of apigenin on cell proliferation, the cells were treated with
apigenin at various doses. In PC-3 and DU-145 cell lines, 10 uM or higher of apigenin
alone significantly decreased cell proliferation (P<0.05, Fig. 4.1). The apigenin has
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similar inhibitory effects on colon cancer cell lines. The apigenin treatment at 15 uM
significantly decreased cell proliferation in colo-205 and HCT-116 (Fig. 4.2). HCT-116
cells were much more sensitive to 15 and 20 uM of apigenin. The effects of apigenin are
similarly observed in other human cancer cells including A549 and H460 cells (Fig. 4.3).

The Combination effects of Apigenin with Chemotherapy Drugs
Doxorubicin: To study the effect of apigenin combined with doxorubicin on cell
proliferation, PC-3 cells were treated by doxorubicin alone or in combination with 15 uM
apigenin. Our data showed that apigenin treatment alone greatly decreased cell
proliferation (Fig. 4.4a). We used a similar method to treat DU-145 cells and found that
apigenin treatment alone was sufficient to inhibit cell proliferation and the addition of
doxorubicin did not further enhance the effect (Fig. 4.4b). For colon cancer cell lines, the
combination treatment of apigenin and doxorubicin has synergistic or additive effects to
inhibit cell proliferation, especially Colo-205 cells (Fig. 4.4c). However, there were no
significant differences with or without the drug treatment in A549 and H460 cells when
combined with apigenin (Fig. 4.4d).

Etoposide: With etoposide treatment in prostate cancer cells, PC-3 (Fig. 4.5a)
cells seemed more sensitive to drug treatment with and without apigenin that did the DU145 (Fig. 4.5b).

Mitomycin C: To study the effect of apigenin combined with the
chemotherapeutic drug mitomycin C, we observed that low doses of mitomycin C were
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sufficient to inhibit cell proliferation in either PC-3 or DU-145 prostate cancer cell lines
and the addition of apigenin increased sensitivity of the cells to mitomycin C (Fig. 4.6a).
In the colon cancer cell lines colo-205 and H460, the effects of the combination therapy
between mitomycin C and apigenin has significantly higher inhibitory effect that
mitomycin C alone(Fig. 4.6b).

Similarly in A549 and H460 lung cancer cell lines, the combination treatment
between mitomycin C and apigenin has significantly higher inhibitory effect than
mitomycin C alone (Fig. 4.6c). Although both showed a significant decrease in cell
proliferation when treating with mitomycin C alone, the inhibitory effect on H460 cell
lines is nearly two-fold stronger than that in A549 cells.

5-Fluorouracil: In PC-3 and DU-145 cells, the combination treatment of
apigenin and 5-fluoruracil alone significantly decreased cell proliferation compared to the
5-fluorouracel alone (Fig. 4.7a). Similarly, the combination treatment of apigenin and 5fluorouracil significantly decreased colo-205 colon cancer cells at 5 and 10 uM than with
5-fluorouracil alone (Fig. 4.7b). The HCT-116 in comparison were much more sensitive
when treated by the combination of apigenin and 5-fluorouracil (Fig. 4.7c)

Cisplatin: The combination treatment of apigenin and cisplatin significantly
decreased cell proliferation at 0.5 and 1 uM cisplatin (Fig. 4.8a). In both colo-205 and the
HCT-116, the synergistic inhibitory effect was no longer observed when the cells were
treated by cisplatin at 5 and 10 uM (Fig. 4.8a). In H460 lung cancer cells, significant
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differences in cell proliferation were observed by the combination treatment than
cisplatin alone (Fig. 4.8b). However, the combination of apigenin and cisplatin did not
significantly affect cell proliferation in A549 cells (Fig. 4.8b).

Conclusions
1. Apigenin, when combined with a range of chemotherapeutic drugs, can increase
the sensitivity of prostate, colon, and lung cancer cells to halt cell proliferation.

Apigenin has been shown previously to be a non-mutagenic, low toxicity
compound, but it is important to keep in mind that each type of cancer would react
differently to treatment with it, as evidenced by the range in IC50 values as described in
Fig. 4.9. Here, apigenin’s ability to increase a cell line’s sensitivity to a particular
chemotherapeutic was measured by its ability to lower IC50 threshold. Based on the
ranges in response, apigenin’s ability to sensitize depends on cell type. While PC-3 cells
show significant differences in combination treatment over doxorubicin, 5-fluorouracil
and mitomycin C treatment alone over DU-145 cells at a range of doses (Fig. 4.4a, 4.4b,
4.6a, 4.6b, 4.7a, and 4.7b), neither the PC-3 nor the DU-145 IC50 were significant (Fig.
4.10a and 4.10b). However, etoposide treatment in both PC-3 and DU-145 cells showed
significant differences in IC50 values (Fig. 4.12a and 4.12b). Similarly, while colo-205
and HCT-116 showed significant differences in combination treatment over single drug
treatment over a range of doses for a number of drugs, significant differences in IC50
values were only seen in doxorubicin and mitomycin C for both and 5-fluorouracil for
HCT-116 (Fig. 4.10c and 4.10d). In lung cancer cells, significant differences in
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combination treatment not seen with single drug treatment in A549 and H460 cells were
found cisplatin and mitomycin C treatment (Fig. 4.10e and 4.10f).

2. When combined with apigenin, IC50 values of potentially toxic
chemotherapeutics on some prostate, lung, and colon cancer cell lines decreased
significantly.

A standard measure of how toxic a particular drug is to an organism is its IC50
value, or the dosage that would be required to kill off have the cells. Here, we measured
IC50 values using cell proliferation. As noted by Figures 4.9 - 4.11 and Table 4.1, there is
a range in how much a drug would be required to hit the IC50 value from cell line to cell
line. However, in most cases, the addition of apigenin alone seemed to significantly
decrease amount of chemotherapeutic drug required to kill off half the cells (Fig. 4.9).
Apigenin combined with doxorubicin exerted the greatest change over drug alone on
IC50 values on PC-3, A549, and H460 cells (Fig. 4.10a), and mitomycin C exerted the
greatest change over drug alone on colon and lung cancer lines (Fig. 4.10b). When
combined with 5-fluorouracil, apigenin showed the greatest effect on IC50 values on
HCT-116 and A549 cells (Fig. 4.10c), and combined with cisplatin, it showed the
greatest effect on DU-145 and colo-205 cells (Fig. 4.10d). On IC50 values from
etoposide treatment, apigenin exerted significantly different effects in combination on
both PC-3 and DU-145 prostate cancer cell lines.
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The possibility of using apigenin in combination is promising. Many naturallyoccurring phenolic compounds are now being to see how their antioxidant effects could
prove useful in decreasing the amount of toxins one must administer in order to undergo
chemotherapy regimens successfully, such as genestein and (-) epigallocatechin-3-gallate.
Apigenin’s properties as an anti-inflammatory make it also intriguing in the realm of
creating new, safe supplements to treat or manage cardiovascular health. Because of its
ability to create the same clinical effect with a reduced amount of chemotherapy and its
ability to potentially treat resistant forms of cancer, apigenin’s involvement in a number
of pathways implicated in variety of cancers makes it an intriguing addition to the recent
focus on nutriceuticals.

Chapter 5: Recommendations
In order to get a more accurate picture of how cancer cells respond to sensitivity
to chemotherapeutics when treated with apigenin, further experiments should be carried
out in normal non-cancerous prostate, lung, and colon cell lines. A comparison of these
cell types to the cancerous variants would give a more complete indication of whether
significant differences of cell proliferation could be seen.

Here, cell death was measured by trypan blue exclusion. For distinction between
apoptosis and necrosis in measures of cell death, more accurate measures of apoptotic
markers such as Annexin V staining or determination of the caspase proteins should be
taken.
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Appendix: Figure Legend
Table 2.1. Subclasses of flavonoids involved in cancer signaling pathways.
Flavanoids are naturally-occuring polyphenol compounds with antioxidant properties.
Many have been implicated to be involved in cell signaling pathways.
Flavonols

myricetin, quercetin

Flavones

apigenin, luteolin

Isoflavones

genistein, luteone

Flavonones

hesperiden, pinocembrin

Flavanols

epicatechin

Anthocyanidins

cyanidin, malvidin
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Table 3.1. Characterization of cell lines.
The PC-3 and DU-145 prostate cancer cell line as well as the Colo-205 colon cancer cell
line have been characterized as having a mutant p53 tumor suppressor status, and
therefore is unable to halt damaged DNA from going through the cell cycle. The HCT116 colon cancer cell line as well as the A549 and H460 lung cancer cell line has been
characterized with normally behaving wild-type p53 tumor suppressor.

Cell line

Origin

P53 status

PC-3

Epithelial prostate
adenocarcinoma

Mutant

DU-145

Epithelial prostate
carcinoma

Mutant

Colo-205

Epithelial colorectal
adenocarcinoma

Mutant

HCT-116

Epithelial colorectal
carcinoma

Wild-type

A549

Epithelial lung
carcinoma

Wild-type

H460

Epithelial lung
carcinoma

Wild-type
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Table 4.1. IC50 values of cell lines.
The IC50 values of cell lines varied with cell type and drug type.
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Figure 2.1. The structure of flavonoids.
The general structure of a flavonoid is comprised of two benzene rings joined by an AC
ring. Certain structural characteristics of flavonoids have been shown to have
antioxidative and anti-inflammative properties.
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Figure 2.2. The structure of apigenin.
Apigenin, also known as 4’, 5, 7 trihydroxyflavone, is a polyphenolic compound that is
found in fruits, vegetables, herbs, and a host of other natural sources. It is classified in the
flavanol group of flavanoids.
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Figure 4.1. Response of prostate cancer cell lines PC-3 and DU-145 to apigenin.
PC-3 and DU-145 cells were plated at 1x104 cells per well in a 96 well plate in 100 uL of
media. They were treated with drug in fresh media for 24 hours. 10 uL of MTT reagent
(thiozolyl blue tetrazolium) was added to each well before incubating for another 2 hours.
Results were read using a spectrophotometer at 470 nm.
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Figure 4.2. Response of colon cancer cell lines colo-205 and HCT-116 to apigenin.
Colo-205 and DU-145 cells were plated at 1x104 cells per well in 100 uL media for a 24
hour drug treatment time. 10 uL of MTT reagent was added to each well before
incubating for another two hours. Results were read using a spectrophotometer at 470
nm. HCT-116 seemed most likely to respond to apigenin treatment at higher doses.
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Figure 4.3. Response of lung cancer cell lines A549 and H460 to apigenin.
While both A549 and H460 lung cancer cells decreased cell proliferation significantly,
A549 lung cancer cells were most sensitive to the apigenin treatment.
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Figure 4.4. Apigenin induced sensitivity of prostate, lung, and colon cancer cell lines
to doxorubicin.
Over a range of doses, PC-3 cells (Fig. 4.4a) treated with apigenin seemed to be more
sensitive to doxorubicin treatment than DU-145 cells (Fig. 4.4b), colo-205 cells seemed
more sensitive at lower doses than HCT-116 cells (Fig. 4.4c), and both A549 and H460
cells seemed to show no trend in significance (Fig. 4.4d).
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Figure 4.5. Apigenin induced sensitivity of the PC-3 and DU-145 prostate cancer cell
lines to etoposide.
PC-3 cells showed a marked sensitivity to etoposide when treated with apigenin in cell
proliferation assay (Fig. 4.5a). DU-145 cells showed more drug resistance to etoposide
than the PC-3 prostate cancer cell line (Fig. 4.5b).
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Figure 4.6. Apigenin induced sensitivity of the prostate, colon, and lung cancer cell
lines to mitomycin C.
Both PC-3 and DU-145 cells showed sensistivity to mitomycin C when treated with
apigenin and measured by cell proliferation assay (Fig. 4.6a). Both colo-205 and HCT116 exhibit apigenin-induced sensitivity, however, HCT-116 cells exhibit a much greater
sensitivity (Fig. 4.6b). Although both showed a significant decrease in cell proliferation
when treating with mitomycin C and apigenin over mitomycin C alone, the H460 cell
lines seems nearly twice as sensitive to the effects of mitomycin C (Fig. 4.6c).

O

Figure 4.7. Apigenin induced sensitivity of the prostate, colon, and lung cancer cell
lines to 5-fluorouracil.
Both PC-3 and DU-145 cell lines exhibited a decrease in cell proliferation, but only the
PC-3 cells did so consistently in a dose-dependent fashion (Fig. 4.7a). While both the
colo-205 (Fig. 4.7b) and HCT-116 (Fig. 4.7c) cells showed a decrease in cell
proliferation with apigenin and 5-fluorouracil, only HCT-116 did so with such a dramatic
matter.
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Figure 4.8. Apigenin induced sensitivity of colon and lung cancer cell lines to
cisplatin.
Apigenin does help increase sensitivity to cisplatin treatment in colon cell proliferation,
but only below 5 uM doses (Fig. 4.8a). Like colon cancer cells, lung cancer cells show
the biggest increase in sensitivity to cisplatin treatment with apigenin at lower doses of
cisplatin (Fig. 4.8b).
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Figure 4.9. IC50’s of prostate, colon, and lung cancer cell lines.
The IC50 value, or the dosage at which half the cells in treatment die, vary from cell type
to cell type. HCT-116 has the highest tolerance for apigenin, while PC-3 and A549 cells
have the lowest tolerable threshold for it.
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Figure 4.10. Comparison of IC50 response to chemotherapeutics with and without
apigenin by drug type.
Apigenin treatment shows the greatest response on IC50 values in PC-3 and DU-145
cells treated with etoposide (Fig. 4.10a and 4.10b), in colo-205 cells treated with 5fluorouracil (Fig. 4.10c), HCT-116 cells treated with mitomycin C (Fig. 4.10d), A549
cells treated with cisplatin (Fig. 4.10e), and H460 cells treated with mitomycin C (Fig.
4.10f).
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Figure 4.11. Comparison of IC50 response to chemotherapeutics with and without
apigenin by cell line.
Response on doxorubicin (Fig. 4.11a), mitomycin (Fig. 4.11b), 5-fluorouracil (Fig.
4.11c), and cisplatin (Fig. 4.11d) varied from cell type to cell type.
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Figure 4.12. Apigenin induced sensitivity of the PC-3 and DU-145 prostate cancer
cell lines to etoposide.
Both PC-3 and DU-145 prostate cancer cells showed a significant response when treated
with apigenin and etoposide over etoposide alone.
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